Eczacıbaşı-Monrol, IBA combine forces to grow
Güncelleme Tarihi:
Hürriyet Daily News
Oluşturulma Tarihi: Şubat 11, 2009 00:00
ISTANBUL - Turkey’s Eczacıbaşı-Monrol and Belgium’s Ion Beam Applications, or IBA, join forces to distribute radiopharmaceuticals. The agreement involves cooperation in the Balkans, Mideast, North Africa, Central and Eastern Europe
Turkey-based Eczacıbaşı-Monrol Nuclear Products and Belgium-based Ion Beam Applications, or IBA, have joined forces for the distribution of radiopharmaceuticals in several markets.
The Memorandum of Understanding signed Monday will enable market growth for Positron Emission Tomography, or PET and Single Photon Emission Computed Tomography, or SPECT, Radiopharmaceuticals in the Balkans, Middle East, North Africa, Central and Eastern Europe.
In the agreement, Eczacıbaşı-Monrol becomes IBA’s preferred partner for the local distribution of IBA diagnostic and therapy SPECT radiopharmaceuticals and new molecules in PET Radiopharmaceuticals, and to enhance the development of Nuclear Medicine. Both companies will also work in close cooperation in those regions on the operation of high-energy cyclotrons for diagnostics and therapy isotopes manufacturing.
Eczacıbaşı-Monrol plans to invest in three more PET radiopharmaceutical (FDG Ğ Fluorodeoxyglucose) production centers on its own to complement its existing five cyclotrons network. IBA will not investing in these Eczacıbaşı-Monrol facilities and they will not contribute directly to IBA’s financial statement, according to a press release posted on Eczacıbaşı-Monrol’s Web site.
IBA can now leverage the largest network of PET Radiopharmaceuticals production and distribution centers in the world, which will be essential to support the launch of new molecules in the PET market.
"This partnership is an important milestone in the expansion of our leading position in the field of Radiopharmaceutical products; it further strengthens our presence in the world. We very much look forward to our enhanced cooperation," said Pierre Mottet, CEO of IBA.
"This strategic partnership will strongly contribute to one of the key strategies of Eczacıbaşı-Monrol, which is to bring new Radiopharmaceutical products to the Nuclear Medicine Society of Turkey and the Region," Sedat Birol, executive vice president of the Eczacıbaşı Healthcare Division.
Joint venture
Eczacıbaşı-Monrol Nuclear Products Industry and Trade, which leads the nuclear medicine industry in Turkey, on July 1, 2008 finalized the share transfer and became a 50:50 joint venture between Monrol Nuclear Products and Eczacıbaşı Pharmaceuticals Manufacturing.
Belgium-based IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.
The Memorandum of Understanding signed Monday will enable market growth for Positron Emission Tomography, or PET and Single Photon Emission Computed Tomography, or SPECT, Radiopharmaceuticals in the Balkans, Middle East, North Africa, Central and Eastern Europe.
In the agreement, Eczacıbaşı-Monrol becomes IBA’s preferred partner for the local distribution of IBA diagnostic and therapy SPECT radiopharmaceuticals and new molecules in PET Radiopharmaceuticals, and to enhance the development of Nuclear Medicine. Both companies will also work in close cooperation in those regions on the operation of high-energy cyclotrons for diagnostics and therapy isotopes manufacturing.
Eczacıbaşı-Monrol plans to invest in three more PET radiopharmaceutical (FDG Ğ Fluorodeoxyglucose) production centers on its own to complement its existing five cyclotrons network. IBA will not investing in these Eczacıbaşı-Monrol facilities and they will not contribute directly to IBA’s financial statement, according to a press release posted on Eczacıbaşı-Monrol’s Web site.
IBA can now leverage the largest network of PET Radiopharmaceuticals production and distribution centers in the world, which will be essential to support the launch of new molecules in the PET market.
"This partnership is an important milestone in the expansion of our leading position in the field of Radiopharmaceutical products; it further strengthens our presence in the world. We very much look forward to our enhanced cooperation," said Pierre Mottet, CEO of IBA.
"This strategic partnership will strongly contribute to one of the key strategies of Eczacıbaşı-Monrol, which is to bring new Radiopharmaceutical products to the Nuclear Medicine Society of Turkey and the Region," Sedat Birol, executive vice president of the Eczacıbaşı Healthcare Division.
Joint venture
Eczacıbaşı-Monrol Nuclear Products Industry and Trade, which leads the nuclear medicine industry in Turkey, on July 1, 2008 finalized the share transfer and became a 50:50 joint venture between Monrol Nuclear Products and Eczacıbaşı Pharmaceuticals Manufacturing.
Belgium-based IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.